264 - Vaccines on the Horizon

Wednesday, October 22, 2025

3:15 PM - 4:30 PM US ET

Location: B405-B407

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Flor Munoz, MD

Associate Professor of Pediatrics
Pediatrics
Baylor College of Medicine Houston
Dallas, Texas, United States
Catherine Mary Healy, MD, FIDSA (she/her/hers)

Associate Professor of Pediatrics
Baylor College of Medicine
Houston, TX, United States

Faculty(s)

Anna Durbin, MD (she/her/hers)

Professor
International Health
Johns Hopkins Bloomberg School of Public Health
Baltimore, MD, United States
David Diemert, MD

Professor of Medicine
George Washington University
Washington, DC, United States
Mandeep Dhingra, MD

Director and Head, R&D Programs
CEPI (Coalition for Epidemic Preparedness Innovations), DC, United States

Disclosure(s):

Flor M. Munoz, MD: Moderna: Board Member; Pfizer: Board Member, Grant/Research Support; Sanofi: Advisor/Consultant

Catherine Mary Healy, MD, FIDSA: Dexcom, Inc: Stocks/Bonds (Public Company); Hillevax, Inc: Advisor/Consultant; Intuitive Surgical, Inc: Stocks/Bonds (Public Company); Quidel Diagnostics: Stocks/Bonds (Public Company); UpToDate Wolters Kluwer Health: Honoraria; Vindico CME: Honoraria

Anna Durbin, MD: Merck and Company, Inc.: I lectured in their vaccine course

David J. Diemert, MD: Merck, Sharpe & Dohme: Advisor/Consultant; Pfizer, Inc.: Advisor/Consultant

Mandeep S. Dhingra, MD: Sanofi: Ex Employee, Stocks/Bonds (Public Company)

Learning Objectives:

At the conclusion of this session, participants will be able to:

analyze current strategies for the prevention of vector borne diseases that are re-emerging, including Dengue, Malaria and Chikungunya;
describe the progress made in the development of vaccines for neglected tropical diseases;
describe the progress in the development of vaccines for Lassa fever;
analyze the use of vaccines for mpox in various populations at risk, including those who are immunocompromised, children and pregnant women.

Presentations:

3:15 PM - 3:40 PM US ET

Vaccines for Neglected Tropical Diseases
Speaker: David J. Diemert, MD – George Washington University
3:40 PM - 4:05 PM US ET

Vaccines for Vector-Borne Pathogens
Speaker: Anna Durbin, MD (she/her/hers) – Johns Hopkins Bloomberg School of Public Health
4:05 PM - 4:30 PM US ET

Vaccines for Emerging Pathogens
Speaker: Mandeep S. Dhingra, MD – CEPI (Coalition for Epidemic Preparedness Innovations)